Dwarfism

Human Growth Hormone Market Size, Share & Trends Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023

The "Human Growth Hormone Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Product, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Growth Hormone Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Product, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global human growth hormone market size is expected to reach USD 14.28 billion by 2030, growing at a CAGR of 12.3% from 2023 to 2030
    The market is witnessing growth due to an increase in the incidence of growth hormone deficiency and other growth-related disorders.
  • In addition, market growth is being driven by intense competition among key players striving to develop innovative and cost-effective treatment options.
  • The increasing parental concerns regarding the growth of their children are contributing to the rising demand for human growth hormone (HGH) therapy.

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

Retrieved on: 
Tuesday, August 1, 2023

People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea.

Key Points: 
  • People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea.
  • TYRA-300 is an oral FGFR3 selective inhibitor whose design may have a meaningful impact on achondroplasia and other skeletal dysplasias.
  • "People living with achondroplasia can have significant health complications that are not adequately addressed with currently available therapies.
  • "The FDA's decision to grant Orphan Drug Designation to TYRA-300 is an important recognition of the potential of our approach to deliver benefit to the achondroplasia community.

Dehumanisation, animalisation: inside the terrible world of Swiss human zoos

Retrieved on: 
Thursday, June 22, 2023

After a stay in Leukerbad, James Baldwin affirmed:

Key Points: 
  • After a stay in Leukerbad, James Baldwin affirmed:
    “From all available evidence, no black man had ever set foot in this tiny Swiss village before I came.
  • Fifty years before the American writer set foot in the Alps, about two third of the Swiss population visited the “Village noir” in Geneva.
  • How is it possible that, half a century later, the exhibition of 200 African people that two million people visited has fallen into oblivion?

A “Black village” in the heart of the Alps

    • Back in 1896, during the Swiss Second National Exhibition, it hosted a human zoo.
    • There are very few visible references to it, except for one street called after its corresponding “white” exhibition, the “Village Suisse”.
    • However, several researchers’ archival work helped unearth the history of the first Swiss “Village noir”.
    • Inhabited by more than 200 individuals from Senegal, the village was situated a few streets from the city’s central square, the Plaine de Plainpalais.

From freak shows to human zoos

    • Far from being a Swiss peculiarity, human zoos were spread around the West.
    • Human exhibitions were a form of entertainment invented in the early 19th century in Great Britain.
    • Turned into a film in 2010, one of the most famous shows was Sara Baartman, the “Hottenton Venus”.
    • Geneva Graduate Institute’s Mohamed Mahmoud Mohamedou suggests that human zoos were common entertainment in the second half of the 19th century.

Two faces of the same racist coin

    • This was when the pseudo-scientific attempts to create a superior race thrived within Western anthropology and biology academic departments.
    • For eugenicists, human zoos provided ‘samples’ for racist theories.
    • Thus, scientific racism developed within academia went hand in hand with popular racism: human zoos were places where these two faces of the same coin met.

Tackling the legacies of human zoos

    • Human exhibitions were the result of Western colonial thinking – says Patrick Minder – in which the Genevan’ “Village noir” fits perfectly.
    • Unlike other countries, Switzerland did not stop its human exhibitions during the interwar period.
    • Against this backdrop, talking about human zoos in Switzerland should not only be of interest to historians.
    • If we keep silent on human zoos, we cannot see how visiting a “typical” Maasai village echoes the old colonial habits of the mise en scène of rural, primitive life.

The Worldwide Recombinant Proteins Industry is Expected to Reach $5 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022

Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth.

Key Points: 
  • Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth.
  • The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.
  • According to the American Cancer Society, in 2022, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths.
  • In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion.

FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism

Retrieved on: 
Friday, November 19, 2021

"With this action, children with short stature due to achondroplasia have a treatment option that targets the underlying cause of their short stature."

Key Points: 
  • "With this action, children with short stature due to achondroplasia have a treatment option that targets the underlying cause of their short stature."
  • People with achondroplasia have a genetic mutation that causes a certain growth regulation gene called fibroblast growth factor receptor 3 to be overly active, which prevents normal bone growth.
  • Voxzogo works by binding to a specific receptor called natriuretic peptide receptor-B that reduces the growth regulation gene's activity and stimulates bone growth.
  • Researchers measured the participants' annualized growth velocity, or rate of height growth, at the end of the year.

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting

Retrieved on: 
Thursday, September 30, 2021

COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients’ lives, today announced presentations featuring new data about its investigational TransCon PTH product candidate at the American Society for Bone & Mineral Research (ASBMR) 2021 Annual Meeting, being held October 1-4 virtually and in-person in San Diego. Presentations will also include an overview of baseline demographics from the Ascendis Pharma-sponsored natural history study of children with achondroplasia.

Key Points: 
  • In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache.
  • HP remains among the few hormonal insufficiency states without an approved replacement therapy that restores the missing hormone at physiologic levels.
  • As a result, patients with HP have an estimated 4-fold to 8-fold greater risk of renal disease compared to healthy controls.
  • SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 25, 2021

COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • TransCon CNP is designed to provide continuous exposure of CNP at safe, therapeutic levels via a single, weekly subcutaneous dose.
  • Ascendis Pharma currently has a pipeline of multiple independent endocrinology rare disease and oncology product candidates in development.
  • SKYTROFA, Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.
  • August 2021 Ascendis Pharma A/S.

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

Retrieved on: 
Tuesday, August 17, 2021

PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, noted that in pre-clinical studies its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to reduce behavioral sensitization underlying addiction to methamphetamine (METH). Behavioral sensitization is widely considered a key neurobiological mechanism in drug addiction.

Key Points: 
  • Behavioral sensitization is widely considered a key neurobiological mechanism in drug addiction.
  • Studies in animal models have shown that dysregulation in the activity of PP2A could be a factor in diseases of the central nervous system, including drug addiction.
  • A recent scientific paper ( Shang et al., NeuroReport, April 2021 ) explains how LB-100, by inhibiting PP2A, blocked METH-induced behavioral sensitization in rodents.
  • Last month, Lixte commented on outside research citing LB-100s PP2A inhibition as a potential therapeutic strategy for triple-negative breast cancer .

Montana Tucker Releases Emotional Official Music Video For "I'm Not Alone"

Retrieved on: 
Monday, July 30, 2018

The official music video for "I'm Not Alone," released today, features dancers with Dwarfism, Down Syndrome, Spinal Bifida, Facial Deformities, plus size dancers, and those who can't hear.

Key Points: 
  • The official music video for "I'm Not Alone," released today, features dancers with Dwarfism, Down Syndrome, Spinal Bifida, Facial Deformities, plus size dancers, and those who can't hear.
  • Led by Tucker however, they excel in a dance; and are given the ability to share their stories.
  • It's been a lifelong mission of mine to help others conquer their fears through dance and music," said Tucker.
  • Her single, "I'm Not Alone," is dedicated to those who have overcome limitations, not only physical but emotional as well.